EUVIMEDEUVIMED entdecken
Open Access

Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms

Tim Kong iD, LaYow Yu, Angelo B A Laranjeira, Daniel A C Fisher, Fan He iD, Maggie J Cox, Stephen T Oh iD

American Journal of Hematology · 2023

DOI: 10.1002/ajh.26935 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Tim Kong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Myeloproliferative Disorders, Bone Marrow Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small molecule inhibitors targeting JAK2 provide symptomatic benefits for myeloproliferative neoplasm (MPN) patients and are among first‐line therapeutic agents. However, despite all having potent capacity to suppress JAK–STAT signaling, they demonstrate distinct clinical profiles suggesting contributory effects in targeting other ancillary pathways. Here, we performed comprehensive profiling on four JAK2 inhibitors either FDA‐approved (ruxolitinib, fedratinib, and pacritinib) or undergoing phase 3 studies (momelotinib) to better outline mechanistic and therapeutic efficacy. Across JAK2 ‐mutant in vitro models, all four inhibitors demonstrated similar anti‐proliferative phenotypes, whereas pacritinib yielded greatest potency on suppressing colony formation in primary samples, while momelotinib exhibited unique erythroid colony formation sparing. All inhibitors reduced leukemic engraftment, disease burden, and extended survival across patient‐derived xenograft (PDX) models, with strongest effects elicited by pacritinib. Through RNA‐sequencing and gene set enrichment analyses, differential suppressive degrees of JAK–STAT and inflammatory response signatures were revealed, which we validated with signaling and cytokine suspension mass cytometry across primary samples. Lastly, we assessed the capacity of JAK2 inhibitors to modulate iron regulation, uncovering potent suppression of hepcidin and SMAD signaling by pacritinib. These comparative findings provide insight into the differential and beneficial effects of ancillary targeting beyond JAK2 and may help guide the use of specific inhibitors in personalized therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase InhibitorsMyeloproliferative DisordersBone Marrow NeoplasmsHumansProtein Kinase InhibitorsJanus Kinase 2BenzamidesPyrimidinesBridged-Ring Compounds

Substanzen

Janus Kinase InhibitorsProtein Kinase InhibitorsJanus Kinase 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamideBenzamidesPyrimidines11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,1…Bridged-Ring Compounds

Autor:innen und Institutionen

  • Division of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Immunomonitoring Laboratory, Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.

ORCID-Profile: Tim Kong, Fan He, Stephen T Oh

Förderung

  • NCI NIH HHS
  • NHLBI NIH HHS
  • NCATS NIH HHS
  • Canadian Institutes of Health Research
  • MPN Research Foundation
  • National Institutes of Health

Zitieren

APA

Kong, T., Yu, L., Laranjeira, A. B. A., Fisher, D. A. C., He, F., Cox, M. J., & Oh, S. T. (2023). Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms. American Journal of Hematology. https://doi.org/10.1002/ajh.26935

Vancouver

Kong T, Yu L, Laranjeira ABA, Fisher DAC, He F, Cox MJ, et al. Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms. American Journal of Hematology. 2023. doi:10.1002/ajh.26935

BibTeX
@article{Kong2023,
  author = {Kong, Tim and Yu, LaYow and Laranjeira, Angelo B A and Fisher, Daniel A C and He, Fan and Cox, Maggie J and Oh, Stephen T},
  title = {Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms},
  journal = {American Journal of Hematology},
  year = {2023},
  doi = {10.1002/ajh.26935}
}
Kostenlos starten →